A Mesut Erzurumluoglu

A Mesut Erzurumluoglu

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2018 in Nature Genetics
Verified
Journal Article
Open access
PDF file
TPThe Million Veteran Program
The Million Veteran Program
EEEvangelos Evangelou
Evangelos Evangelou
HWHelen R. Warren
Helen R. Warren
DMDavid Mosen-Ansorena
David Mosen-Ansorena
BMBorbala Mifsud
Borbala Mifsud
MCMark Caulfield
Mark Caulfield
High blood pressure is a highly heritable and modifiable risk factor for cardiovascular disease. We report the largest genetic association study of blood pressure traits (systolic, diastolic and pulse pressure) to date in over 1 million people of European ancestry. We identify 535 novel blood pressure loci that not only offer new biological insights into blood pressure regulation but also highlight shared genetic architecture between blood pressure and lifestyle exposures. Our findings identify new biological pathways for blood pressure regulation with potential for improved cardiovascular disease prevention in the future.

22 September 2016 in Bioinformatics
Verified
Journal Article
Open access
PDF file
JZJie Zheng
Jie Zheng
AEA Mesut Erzurumluoglu
A Mesut Erzurumluoglu
BEBenjamin L Elsworth
Benjamin L Elsworth
JKJohn P Kemp
John P Kemp
LHLaurence Howe
Laurence Howe
BNBenjamin M Neale
Benjamin M Neale
LD score regression is a reliable and efficient method of using genome-wide association study (GWAS) summary-level results data to estimate the SNP heritability of complex traits and diseases, partition this heritability into functional categories, and estimate the genetic correlation between different phenotypes. Because the method relies on summary level results data, LD score regression is computationally tractable even for very large sample sizes. However, publicly available GWAS summary-level data are typically stored in different databases and have different formats, making it difficult to apply LD score regression to estimate genetic correlations across many different traits simultaneously. In this manuscript, we describe LD Hub - a centralized database of summary-level GWAS results for 173 diseases/traits from different publicly available resources/consortia and a web interface that automates the LD score regression analysis pipeline. To demonstrate functionality and validate our software, we replicated previously reported LD score regression analyses of 49 traits/diseases using LD Hub; and estimated SNP heritability and the genetic correlation across the different phenotypes. We also present new results obtained by uploading a recent atopic dermatitis GWAS meta-analysis to examine the genetic correlation between the condition and other potentially related traits. In response to the growing availability of publicly accessible GWAS summary-level results data, our database and the accompanying web interface will ensure maximal uptake of the LD score regression methodology, provide a useful database for the public dissemination of GWAS results, and provide a method for easily screening hundreds of traits for overlapping genetic aetiologies. The web interface and instructions for using LD Hub are available at http://ldsc.broadinstitute.org/ Supplementary data are available at Bioinformatics online.

10 February 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
TCThe Endometrial Cancer Association Consortium
The Endometrial Cancer Association Consortium
KRKatherine S Ruth
Katherine S Ruth
FDFelix R Day
Felix R Day
JTJessica Tyrrell
Jessica Tyrrell
DTDeborah J Thompson
Deborah J Thompson
JPJohn R. B. Perry
John R. B. Perry

25 February 2019 in Nature Genetics
Verified
Journal Article
Open access
PDF file
NSNick Shrine
Nick Shrine
AGAnna L. Guyatt
Anna L. Guyatt
AEA Mesut Erzurumluoglu
A Mesut Erzurumluoglu
VJVictoria E. Jackson
Victoria E. Jackson
BHBrian D. Hobbs
Brian D. Hobbs
UGUnderstanding Society Scientific Group
Understanding Society Scientific Group
Reduced lung function predicts mortality and is key to the diagnosis of chronic obstructive pulmonary disease (COPD). In a genome-wide association study in 400,102 individuals of European ancestry, we define 279 lung function signals, 139 of which are new. In combination, these variants strongly predict COPD in independent populations. Furthermore, the combined effect of these variants showed generalizability across smokers and never smokers, and across ancestral groups. We highlight biological pathways, known and potential drug targets for COPD and, in phenome-wide association studies, autoimmune-related and other pleiotropic effects of lung function–associated variants. This new genetic evidence has potential to improve future preventive and therapeutic strategies for COPD.

6 February 2017 in Nature Genetics
Verified
Journal Article
Open access
PDF file
UGUnderstanding Society Scientific Group
Understanding Society Scientific Group
LWLouise V Wain
Louise V Wain
GCGeisinger-Regeneron DiscovEHR Collaboration
Geisinger-Regeneron DiscovEHR Collaboration
NSNick Shrine
Nick Shrine
MAMaría Soler Artigas
María Soler Artigas
MTMartin D Tobin
Martin D Tobin
Louise Wain, Ian Hall, Martin Tobin and colleagues report genome-wide association analyses of lung function, identifying 43 new signals associated with one or more lung function traits. A genetic risk score derived from these results was significantly associated with risk for chronic obstructive pulmonary disease in independent populations. Chronic obstructive pulmonary disease (COPD) is characterized by reduced lung function and is the third leading cause of death globally. Through genome-wide association discovery in 48,943 individuals, selected from extremes of the lung function distribution in UK Biobank, and follow-up in 95,375 individuals, we increased the yield of independent signals for lung function from 54 to 97. A genetic risk score was associated with COPD susceptibility (odds ratio per 1 s.d. of the risk score (∼6 alleles) (95% confidence interval) = 1.24 (1.20–1.27), P = 5.05 × 10−49), and we observed a 3.7-fold difference in COPD risk between individuals in the highest and lowest genetic risk score deciles in UK Biobank. The 97 signals show enrichment in genes for development, elastic fibers and epigenetic regulation pathways. We highlight targets for drugs and compounds in development for COPD and asthma (genes in the inositol phosphate metabolism pathway and CHRM3) and describe targets for potential drug repositioning from other clinical indications.

1 September 2017 in Hypertension
Verified
Journal Article
Open access
LWLouise V. Wain
Louise V. Wain
AVAhmad Vaez
Ahmad Vaez
RJRick Jansen
Rick Jansen
RJRoby Joehanes
Roby Joehanes
PMPeter J. van der Most
Peter J. van der Most
GEGeorg B. Ehret
Georg B. Ehret
Elevated blood pressure is a major risk factor for cardiovascular disease and has a substantial genetic contribution. Genetic variation influencing blood pressure has the potential to identify new pharmacological targets for the treatment of hypertension. To discover additional novel blood pressure loci, we used 1000 Genomes Project–based imputation in 150 134 European ancestry individuals and sought significant evidence for independent replication in a further 228 245 individuals. We report 6 new signals of association in or near HSPB7 , TNXB , LRP12 , LOC283335 , SEPT9 , and AKT2 , and provide new replication evidence for a further 2 signals in EBF2 and NFKBIA . Combining large whole-blood gene expression resources totaling 12 607 individuals, we investigated all novel and previously reported signals and identified 48 genes with evidence for involvement in blood pressure regulation that are significant in multiple resources. Three novel kidney-specific signals were also detected. These robustly implicated genes may provide new leads for therapeutic innovation.